The human brain is arguably the most complex structure in the known universe, and maintaining its health across the lifespan represents one of the greatest challenges in modern medicine. As Australia’s population ages, cognitive decline and neurodegenerative diseases are becoming increasingly prevalent — dementia alone affects over 400,000 Australians, with numbers projected to exceed 1 million by 2058.
Cognitive peptides offer a fascinating approach to brain health research, providing targeted tools for investigating neuroprotection, cognitive enhancement, and neuroplasticity. Unlike broad-spectrum nootropics, these peptides work through specific, well-characterised mechanisms that allow researchers to probe the intricate biology of brain function with precision.
In this comprehensive guide, we explore two of the most extensively researched cognitive peptides available in Australia: Semax and Selank. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, these peptides have been the subject of decades of research and have demonstrated remarkable effects on brain function, mood regulation, and neuroprotection.
Cognitive function depends on the coordinated activity of billions of neurons communicating through trillions of synaptic connections. This neural network is maintained by a complex interplay of neurotransmitters, neurotrophic factors, and glial cell support systems. When any component of this network is disrupted — whether by ageing, disease, injury, or stress — cognitive function can decline.
Cognitive peptides work by supporting and enhancing the brain’s natural maintenance and repair systems. Key mechanisms include increasing the production of brain-derived neurotrophic factor (BDNF) — often called “fertiliser for the brain” — modulating neurotransmitter systems, reducing neuroinflammation, and promoting neuroplasticity (the brain’s ability to form new connections and adapt to new challenges).
Research published in Nature Neuroscience has established that neurotrophic factors like BDNF play critical roles in learning, memory formation, and neuronal survival. Peptides that can enhance BDNF expression therefore have the potential to support cognitive function across multiple domains.
Semax (10mg) is a synthetic analogue of adrenocorticotropic hormone (ACTH) fragment 4-10, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Developed in the 1980s at the Institute of Molecular Genetics in Moscow, Semax has been extensively studied for its nootropic (cognitive-enhancing), neuroprotective, and neurorestorative properties.
Semax exerts its cognitive effects through multiple complementary mechanisms. Its primary action involves the upregulation of BDNF and its receptor TrkB in the hippocampus and prefrontal cortex — brain regions critical for learning, memory, and executive function. Research published in Neuroscience Letters demonstrated that Semax administration significantly increased BDNF mRNA expression in the rat hippocampus, with effects lasting well beyond the peptide’s plasma half-life.
Beyond BDNF modulation, Semax influences several neurotransmitter systems. Studies have shown that the peptide can modulate dopaminergic, serotonergic, and cholinergic neurotransmission — all systems critically involved in cognitive function, mood regulation, and attention. Semax has also been shown to enhance the expression of nerve growth factor (NGF) and neurotrophin-3 (NT-3), providing broad neurotrophic support.
Semax has been studied extensively in both animal models and human clinical settings. In Russia, where it has been approved as a pharmaceutical agent, Semax has been used in research on stroke recovery, cognitive impairment, and attention deficit disorders.
In stroke research, Semax has demonstrated remarkable neuroprotective effects. A clinical study published in Zhurnal Nevrologii i Psikhiatrii found that Semax administration within the first hours of ischaemic stroke improved neurological outcomes and reduced infarct volume. The peptide’s ability to enhance BDNF expression in the peri-infarct region is thought to promote neuroplasticity and functional recovery.
In cognitive enhancement research, Semax has shown the ability to improve attention, memory consolidation, and learning speed in both healthy subjects and those with cognitive impairment. Animal studies have demonstrated that Semax can enhance performance in maze navigation tasks, object recognition tests, and passive avoidance paradigms — standard measures of spatial memory, recognition memory, and associative learning.
Semax has also shown promise in research on neurodegenerative conditions. Studies have demonstrated that the peptide can protect neurons from oxidative stress, reduce neuroinflammation, and inhibit amyloid-beta aggregation — a hallmark of Alzheimer’s disease. These findings have significant implications for Australian dementia research, given the country’s growing burden of neurodegenerative disease.
Additionally, Semax has been investigated for its effects on gene expression in the brain. A comprehensive genomic study published in BMC Neuroscience found that Semax modulated the expression of over 100 genes in the rat brain, including genes involved in neurotransmission, immune response, vascular function, and cell survival. This broad genomic effect suggests that Semax’s cognitive benefits arise from a coordinated modulation of multiple biological pathways rather than a single mechanism.
Selank (10mg) is a synthetic analogue of the naturally occurring immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Like Semax, Selank was developed at the Institute of Molecular Genetics and has been extensively studied for its anxiolytic (anti-anxiety), nootropic, and immunomodulatory properties.
Selank’s primary mechanism involves modulation of the GABAergic system — the brain’s main inhibitory neurotransmitter network. Research has shown that Selank can enhance GABA-mediated neurotransmission, producing anxiolytic effects comparable to benzodiazepines but without the sedation, cognitive impairment, or addiction potential associated with these drugs.
Beyond its GABAergic effects, Selank influences the balance of monoamine neurotransmitters, including serotonin, dopamine, and norepinephrine. Research published in Bulletin of Experimental Biology and Medicine demonstrated that Selank can stabilise the metabolism of these neurotransmitters, contributing to its mood-regulating and cognitive-enhancing effects.
Selank also shares some of Semax’s neurotrophic properties, with studies showing that it can increase BDNF expression in the hippocampus. This dual anxiolytic-nootropic profile makes Selank particularly valuable for research investigating the relationship between anxiety, stress, and cognitive function.
Selank has been studied extensively for its anxiolytic properties. Clinical research has demonstrated that the peptide can reduce anxiety symptoms in patients with generalised anxiety disorder, with efficacy comparable to benzodiazepines but with a significantly better side effect profile. Importantly, Selank does not produce sedation, muscle relaxation, or cognitive impairment — common drawbacks of traditional anxiolytic medications.
In cognitive research, Selank has shown the ability to improve memory and learning, particularly under conditions of stress. This is significant because stress is one of the most potent inhibitors of cognitive function, and interventions that can maintain cognitive performance under stress have both research and practical applications. Studies have demonstrated that Selank can prevent stress-induced memory impairment and maintain hippocampal function during chronic stress exposure.
Selank’s immunomodulatory properties add another dimension to its research profile. Studies have shown that the peptide can modulate cytokine expression, enhance natural killer cell activity, and regulate inflammatory responses. Research published in Immunology Letters demonstrated that Selank influences the expression of genes involved in immune regulation, suggesting a link between its anxiolytic and immunomodulatory effects — a connection that aligns with the growing understanding of the gut-brain-immune axis.
For Australian researchers, Selank’s combined anxiolytic and cognitive effects are particularly relevant given the high prevalence of anxiety disorders in Australia. According to the Australian Bureau of Statistics, anxiety is the most common mental health condition in Australia, affecting approximately 3.3 million people. Research into peptide-based anxiolytics that don’t compromise cognitive function represents an important avenue for improving mental health outcomes.
While Semax and Selank share some mechanisms (particularly BDNF upregulation), they offer distinct and complementary profiles for cognitive research. Semax is primarily a nootropic and neuroprotective agent, excelling in research on cognitive enhancement, stroke recovery, and neurodegeneration. Selank is primarily an anxiolytic with nootropic properties, making it ideal for research on anxiety-cognition interactions, stress resilience, and immune-brain communication.
Some researchers have investigated the combination of both peptides, hypothesising that their complementary mechanisms could produce synergistic cognitive benefits. While more research is needed to fully characterise these interactions, preliminary findings suggest that the combination may offer broader neuroprotective and cognitive-enhancing effects than either peptide alone.
Australia boasts world-class neuroscience research institutions, including the Florey Institute of Neuroscience and Mental Health in Melbourne and the Queensland Brain Institute in Brisbane. These institutions are actively investigating novel approaches to neuroprotection, cognitive enhancement, and neurodegenerative disease treatment.
The intersection of cognitive peptide research with Australia’s ageing population creates compelling research opportunities. As the prevalence of dementia, cognitive decline, and mood disorders increases, the need for effective, well-tolerated interventions becomes ever more pressing. Cognitive peptides like Semax and Selank offer promising research tools for addressing these challenges.
Researchers interested in complementary approaches to brain health may also want to explore our anti-ageing peptides, which address the cellular ageing processes that underlie neurodegeneration, or our healing peptides like BPC-157, which has shown neuroprotective properties through its effects on the dopaminergic system.
Cognitive peptides represent a sophisticated approach to brain health research, offering targeted tools for investigating the complex biology of cognition, mood, and neuroprotection. Semax‘s powerful nootropic and neuroprotective effects, combined with Selank‘s unique anxiolytic-cognitive profile, provide Australian researchers with a comprehensive toolkit for advancing our understanding of brain function and developing new approaches to cognitive health.
As neuroscience continues to unravel the mysteries of the brain, cognitive peptides will play an increasingly important role in translating basic research into practical health solutions. Explore our complete range of cognitive peptides and contribute to the next breakthrough in brain health research.
Australia’s leading supplier of high-purity research peptides. Committed to scientific excellence and fast, secure domestic distribution.
Research Disclaimer: All products sold by Aus Bio Peps are strictly for laboratory research and development purposes only. These products are not for human consumption, medical, or diagnostic use. Please consult the TGA guidelines regarding research chemicals.
© 2026 Aus Bio Peps. All Rights Reserved. Based in Australia.
